Top Tech Companies (32)
Over the past two decades, has built Australia's leading marketplace connecting Business & Healthcare Providers. We create innovative solutions using our medEbridge platform and our marketplace of healthcare providers to enable you to achieve your business objectives. medEbridge allows businesses to access GPs, Specialists, Nurses, Allied Health Providers and more. Our business customers include life insurers, compulsory third party insurers, workers compensation insurers, legal firms, employers and government agencies. Current information and services procured include treating doctor reports, medical file copies, independent medical examinations, peer reviews, medical advice, health assessments, eForms, vaccinations and tele-interviews
Halaxy makes healthcare better all over the world. Halaxy is a platform for patients, practitioners and people everywhere, and provides: 1. Practice management software (EMR, billing and scheduling) for any practitioner of any profession in any practice anywhere in the world; 2. Searchable practitioner directories covering 50% of the English speaking world enabling people to find the right practitioner for them; 3. Clinical tools to track your health for people to improve their health, manage conditions and bring together all their health information in the one place; and 4. Personally controlled shared health records. Halaxy is also a leader in telehealth and online consultations platforms, and health informatics. Halaxy solves the underlying issues of healthcare to make healthcare efficient, effective and accessible wherever you are in the world.
Zipline is a "Fast100" startup automating 'Frontline Compliance' workflows HealthCare organisations in Australia & USA. Loved by customers in Health Care such as St Vincent’s, Regis, Calvary and many more. Our Customer Experience RateIt product captures in-the-moment customer sentiment for customers such as Adidas, Coles, Mitre10 and many more. Our 6Q product provides weekly Employee Pulse Surveys, tracking team mood for RAC, Seven West Media and many more. And YES we’re hiring… so please reach out to Jack - our friendly head of talent - to chat.
At See-Mode, our mission is to unlock the hidden insights in medical imaging with AI, and empower clinicians to improve patient outcomes. Our AI-enhanced ultrasound reporting software automatically reads and assesses ultrasound images, producing accurate clinical reports.
Montu is Australia's leading health tech business revolutionising the alternative health landscape. Montu has built an integrated ecosystem, which streamlines the experience for patients end-to-end, and sets new standards. The company is committed to improve the lives of millions of patients
CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global and diversified biopharmaceutical company focused on developing and commercialising treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL’s research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair and acute or life threatening conditions. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 and the US Food and Drug Administration in 2019 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information please go to http://www.clinuvel.com. SCENESSE® and PRÉNUMBRA® are registered trademarks of CLINUVEL PHARMACEUTICALS LTD
Since 1993, EPAM Systems, Inc. (NYSE: EPAM) has leveraged its software engineering expertise to become a leading global product development, digital platform engineering, and top digital and product design agency. Through its ‘Engineering DNA’ and innovative strategy, consulting, and design capabilities, EPAM works in collaboration with its customers to deliver next-gen solutions that turn complex business challenges into real business outcomes. EPAM’s global teams serve customers in more than 45 countries across five continents. As a recognized market leader in multiple categories among top global independent research agencies, EPAM was one of only four technology companies to appear on Forbes 25 Fastest Growing Public Tech Companies list every year of publication since 2013 and ranked as the top IT services company on Fortune’s 100 Fastest-Growing Companies list in 2019, 2020, and 2021.
Seer is a medical technology company on a mission to give people more control of their most valuable assets—their health and their time—by reimagining how and where they undergo long-term clinical monitoring. Seer's products and services are focused on solving the problems related to the early and accurate diagnosis of epilepsy. Seer’s flagship suite of technologies, offered through a provider partnership service called Seer Home, is an FDA-cleared Class II medical device that delivers a revolutionary home-based video-EEG-ECG monitoring solution for seizure disorders and related conditions.
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing review of independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.
Advancing the world’s transition to AI-supported healthcare.
Mayne Pharma is an ASX-listed specialty pharmaceutical Company (ASX: MYX) focused on commercializing novel and generic pharmaceuticals. We offer patients better, safe and more accessible medicines. Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialized in numerous products that continue to be marketed around the world. Mayne Pharma also has a full service contract development and manufacturing organizations (CDMO) servicing clients worldwide: Mayne Contract Services is based in Salisbury, SA, Australia Here are some key facts about our company: • 400+ staff • A$500m+ market cap • A$400m+ in revenue (FY22) • A product portfolio of 90+ marketed products globally The Company's corporate values are: • Empowerment – encouraging everyone to take initiative, enabling growth and achievement. • Passion – showing pride, enthusiasm and dedication in everything we do. • Creativity – delivering value and striving to connect new ideas with business realities. • Agility – operating with timeliness as well as mental, emotional and physical flexibility. • Integrity – maintaining high ethical standards, demonstrating honesty, and respecting fairness by doing the right thing, even when no one is looking. • Accountability – accepting our individual and team responsibilities, meeting our commitments, and acknowledging and learning from mistakes. To learn more, visit us at www.maynepharma.com. Our social media policy: https://bit.ly/3py3L1e Any communication you receive from Mayne Pharma will never come from a personal email domain or chat service such as "gmail" or "Google Chat". All official communication from Mayne Pharma will be received from our company email domain - @maynepharma.com.
Nanochap is a fabless semiconductor company with its core R&D team based in Melbourne, Australia. We specialise in neural interface and biosensing SoCs. The company is committed to the R&D, design, packaging, testing, and commercialisation of ultra-high density neural interface chips, biosensing chips, and other medical device related chips.
